CREBBP and acute lymphoblastic leukemia: Overall, these findings demonstrate that: (i) oral Venetoclax can be highly efficacious in controlling CREBBP-mutated B-ALL in preclinical in-vivo models; and (ii) pharmacological inhibition of CREBBP is a tolerable and effective means of sensitizing B-ALL to Venetoclax in-vivo.